Telmisartan attenuates cognitive impairment caused by chronic stress in rats

Wincewicz, Dominik; Braszko, Jan J.

doi:10.1016/j.pharep.2013.11.002

Cited by 46 publications

(35 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In response to stress, some people lose weight, whereas others gain it. Chronic restraint stress in male Wistar rats reduced body weight gain compared with nonstressed animals (50). In the present study, neither visceral nor subcutaneous fat mass was significantly affected by restraint stress, whereas body weight was significantly reduced by such stress in a manner sensitive to propranolol.…”

Section: Discussioncontrasting

confidence: 73%

Restraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome

Matsuura

Nagasawa

Minagawa

et al. 2015

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Restraint stress stimulates sympathetic nerve activity and can affect adiposity and metabolism. However, the effects of restraint stress on cardiovascular and metabolic disorders in metabolic syndrome (MetS) have remained unclear. We investigated the effects of chronic restraint stress and β-adrenergic receptor (β-AR) blockade on cardiac and adipose tissue pathology and metabolic disorders in a rat model of MetS. DahlS.Z-Lepr(fa)/Lepr(fa) (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats. Rats were exposed to restraint stress (restraint cage, 2 h/day) for 4 wk from 9 wk of age with or without daily subcutaneous administration of the β-AR blocker propranolol (2 mg/kg). Age-matched homozygous lean littermates of DS/obese rats (DahlS.Z-Lepr(+)/Lepr(+) rats) served as control animals. Chronic restraint stress exacerbated hypertension as well as left ventricular hypertrophy, fibrosis, diastolic dysfunction, and oxidative stress in a manner sensitive to propranolol treatment. Restraint stress attenuated body weight gain in DS/obese rats, and this effect tended to be reversed by propranolol (P = 0.0682). Restraint stress or propranolol did not affect visceral or subcutaneous fat mass. However, restraint stress potentiated cardiac and visceral adipose tissue inflammation in DS/obese rats, and these effects were ameliorated by propranolol. Restraint stress also exacerbated glucose intolerance, insulin resistance, and abnormal lipid metabolism in a manner sensitive to propranolol. In addition, restraint stress increased urinary norepinephrine excretion, and propranolol attenuated this effect. Our results thus implicate β-ARs in the exacerbation of cardiac and adipose tissue pathology and abnormal glucose and lipid metabolism induced by restraint stress in this model of MetS.

show abstract

Section: Discussioncontrasting

confidence: 73%

Restraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome

Matsuura

Nagasawa

Minagawa

et al. 2015

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…A recent animal study reported that telmisartan attenuates cognitive impairment caused by chronic stress in rats . Studies have also reported that ARBs protect against cognitive deterioration in patients with mild cognitive impairment and may delay the progression of Alzheimer's disease .…”

Section: Discussionmentioning

confidence: 99%

The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia

Fan

Song

Zhao

et al. 2017

Acta Psychiatr Scand

View full text Add to dashboard Cite

Objective This study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine or clozapine treated patients with schizophrenia. Methods In a 12-week randomized, double blind, placebo controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received either telmisartan (80mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Negative Symptoms (SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12. Results Fifty-four subjects were randomized and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared to the placebo group (mean ± SD: −4.1 ± 8.1 versus 0.4 ± 7.5, p=0.038, Cohen’s d=0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score or any cognitive measures (p’s > 0.100). Conclusion The present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.

show abstract

“…29 Therefore, to broaden utility of this study all three paradigms were used (MWM, RAM, and BM) as it might become relevant to neurodegenerative and neuropsychiatric illnesses where cognition is impaired. [30][31][32] As a continuation of our previous studies, 9 and screening for compounds with potential cognitive enhancing effects, as well as delineating deleterious effects of stress on cognition, we proceeded with development studies of telmisartan. The results of the present study clearly demonstrate that pre-treatment with telmisartan significantly reduces stress-related cognitive impairment in rats.…”

Section: Discussionmentioning

confidence: 99%

“…7 However, this effect might be reduced by suppression of the brain RAS system, as we have previously shown using highly selective angiotensin type one (AT 1 ) receptor blockade, which effectively prevented deleterious effects of chronic stress on retrieval of memory in rats. 8,9 In this study, we attempted to evaluate the effect of AT 1 receptor blockade using telmisartan in hippocampaldependent memory tasks. Spatial and non-spatial cognition are two important aspects of cognitive function.…”

Section: Introductionmentioning

confidence: 99%

Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress

Wincewicz

Braszko

2014

J Renin Angiotensin Aldosterone Syst

Self Cite

View full text Add to dashboard Cite

show abstract

Telmisartan attenuates cognitive impairment caused by chronic stress in rats

Abstract: It appears that telmisartan may constitute a new therapeutic option in a stress-related cognitive impairment.

Cited by 46 publications

References 50 publications

Restraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome

Restraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome

The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia

Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress

Contact Info

Product

Resources

About